Related Experiment Video

Updated: Aug 7, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib: a newly approved small-molecule inhibitor of angiogenesis

Elwyn Cabebe1, Heather Wakelee

  • 1Division of Medical Oncology, Stanford University, Stanford, California 94305, USA.

Drugs of Today (Barcelona, Spain : 1998)
|July 18, 2006
PubMed

Insights

Sunitinib, a targeted therapy, shows antitumor and antiangiogenic effects by inhibiting receptor tyrosine kinases. It is approved for gastrointestinal stromal tumors and renal cell cancer, with ongoing trials in other malignancies.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Targeted therapies are revolutionizing cancer treatment by inhibiting tumor growth pathways.
  • Sunitinib is an oral, small-molecule, multitargeted receptor tyrosine kinase inhibitor.
  • It exhibits direct antitumor activity and antiangiogenic properties.

Purpose of the Study:

  • To review the development and therapeutic applications of sunitinib.
  • To discuss sunitinib's efficacy in gastrointestinal stromal tumors and renal cell cancer.
  • To explore ongoing and future trials of sunitinib in various malignancies.

Main Methods:

  • Review of preclinical and clinical data on sunitinib.
  • Analysis of sunitinib's mechanism of action, targeting VEGFR, PDGFR, and other kinases.
  • Examination of regulatory approvals and ongoing clinical trials.

Main Results:

  • Sunitinib targets key receptor tyrosine kinases involved in tumor growth and angiogenesis.
  • Approved for gastrointestinal stromal tumors (GIST) and metastatic renal cell cancer (RCC).
  • Demonstrated antitumor activity and antiangiogenic effects.

Conclusions:

  • Sunitinib is an effective targeted therapy for specific cancers.
  • Ongoing research is expanding its use in other malignancies and combination therapies.
  • Future development holds promise for broader oncological applications.

More Related Videos

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-308:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...